cdc7

PHA-767491 (CAY10572) is a potent ATP-competitive dual Cdc7 CDK9 inhibitor with IC50 of 10 nM and 34 nM, respectively.

PHA-767491 hydrochloride (CAY-10572 hydrochloride) is an effective ATP-competitive dual Cdc7 CDK9 inhibitor (IC50: 10 34 nM). It has ~20-fold selectivity against GSK3-β and CDK1 2, 50-fold selectivity against CDK5 and MK2, 100-fold selectivity against CHK2 and PLK1.

LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].

LY3177833 is an Cdc7 kinase inhibitor (IC50 : 3.3 nM)

Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.

Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.

Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC50 of 1.49 nM [1].

Cdc7-IN-14 (compound 82) is a highly potent CDC7 inhibitor with an IC50 value of less than 1 nM, exhibiting promising potential for cancer research [1].

Cdc7-IN-11 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in the study of proliferative diseases.

Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].

Cdc7-IN-12 (compound 1) is a potent CDC7 inhibitor (IC50 < 1 nM) with potential applications in cancer research, demonstrating antiproliferative activity in COLO205 cells with an IC50 of 100-1000 nM [1].

Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.

Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.

Cdc7-IN-15 (Example 108) is a cdc7 kinase inhibitor with potential applications in cancer research [1].

(S)-Cdc7-IN-18, a potent CDC7 inhibitor, effectively impedes the overactivation of MCM2, a crucial tumor cell marker, induced by huCdc7 overexpression. Consequently, it inhibits the aberrant proliferation of tumor cells. This compound, exhibits promise for cancer disease research [1].

Cdc7-IN-8, a potent inhibitor, targets Cdc7, a serine threonine kinase responsible for activating MCM promotion through phosphorylation of the microchromosome maintenance protein (MCM protein). MCM protein, an essential component of DNA replication initiation, plays a crucial role. Cdc7-IN-8 holds promise in cancer disease research (WO2021032170A1, compound 1-1 1-2) [1].

Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor with an IC50 value of less than 1 nM, showing significant potential for cancer research [1].

Cdc7-IN-18 (compound 1-2) is a highly effective inhibitor of the CDC7 enzyme, with an IC50 value of 1.29 nM for the Cdc7 DBF4 enzyme. Additionally, this compound exhibits strong antiproliferative activities, with an IC50 value of 53.62 nM in COLO205 cells [1].

Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and effectively induces cell death.

Cdc7-IN-10 is a potent inhibitor of Cdc7 (IC50 ≤ 1 nM) and can be used in studies of proliferative diseases.

Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC50 of <10 μM, applicable in cancer research [1].

XL413 HCl is an ATP-competitive Cdc7 inhibitor (IC50: 3.4 nM) that is potent and selective.XL413 HCl inhibited CK2 and PIM1 with IC50 values of 215 and 42 nM, respectively.XL413 HCl showed an EC50 value of 118 against pMCM.

Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase. Cdc7, a serine-threonine protein kinase enzyme, is essential for the initiation of DNA replication in the cell cycle.

XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. XL-413 binds to and inhibits the activity of CDC7, which may result in the inhibition of DNA replication and mitosis, the induct